Skip to content

IVIEW Therapeutics

2 viewers · 30d

Total raised

$9.2M

2 filings since 2024 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $9.2M
ROUNDS
2
INVESTORS
4
FOUNDED
N/A
HQ
Cranbury, NJ
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
2

AI overview

Updated

IVIEW Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing innovative treatments for ocular diseases. By focusing on unmet medical needs in the ophthalmology sector, the company aims to create effective therapies for conditions including dry eye disease, conjunctivitis, myopia, glaucoma, and presbyopia.

What sets it apart

IVIEW stands out with its novel delivery methods and mechanisms of action, particularly its ophthalmic eyelid wipe for dry eye disease, which offers a differentiated approach in treatment.

Funding history

2 rounds
EquityMay 14, 2024
Form D/A
+$7.7M$9.2M total
EquityMay 14, 2024
Form D/A
+$9.2M$9.2M total

Products

1 tracked

IVW-1001

Ocular treatment

IVW-1001 is a novel TRPM8 agonist specifically designed for the treatment of dry eye disease. This innovative product is delivered via an ophthalmic eyelid wipe, ensuring both ease of use and targeted action directly at the affected area.

  • Novel TRPM8 agonist mechanism of action
  • Unique ophthalmic eyelid wipe delivery system
  • Positive results from Phase 1/2 clinical trials regarding safety and efficacy

Links

WebsiteSEC EDGAR filings